The evaluation and management of drug effects on cardiac conduction (PR and QRS intervals) in clinical development.

Recent advances in electrocardiographic monitoring and waveform analysis have significantly improved the ability to detect drug-induced changes in cardiac repolarization manifested as changes in the QT/corrected QT interval. These advances have also improved the ability to detect drug-induced changes in cardiac conduction. This White Paper summarizes current opinion, reached by consensus among experts at the Cardiac Safety Research Consortium, on the assessment of electrocardiogram-based safety measurements of the PR and QRS intervals, representing atrioventricular and ventricular conduction, respectively, during drug development. Copyright © 2013 Mosby, Inc. All rights reserved.

Citation

Adel Nada, Gary A Gintant, Robert Kleiman, David E Gutstein, Christer Gottfridsson, Eric L Michelson, Colette Strnadova, Matthew Killeen, Mary Jane Geiger, Mónica L Fiszman, Luana Pesco Koplowitz, Glenn F Carlson, Ignacio Rodriguez, Philip T Sager. The evaluation and management of drug effects on cardiac conduction (PR and QRS intervals) in clinical development. American heart journal. 2013 Apr;165(4):489-500

Mesh Tags

Substances

PMID: 23537964

search → result